Ready-to-use stem cell kits for pets coming soon? Gallant closes $18M Series B funding
Founded by Aaron Hirschhorn, Gallant is looking to develop the first off-the-shelf stem cell therapy kits in veterinary medicine that has been approved by the US Food and Drug Administration (FDA).
Its latest funding round was led by existing backer Digitalis Venture and also saw participation from NovaQuest Capital Management, which has invested in human stem cell therapy in the past. So far, the company has raised a total of $44 million from investors.
Hirschhorn, who passed away in 2021, started Gallant after selling pet-sitting network DogVacay to its biggest rival Rover, according to a report by TechCrunch. 'We're honored to have the backing of partners who share our vision in creating this new category of medicine that doesn't just help pets feel better, but helps pets get better,' said Dr Linda Black, CEO of Gallant.
'The FDA approval of the first human allogeneic stem cell therapy was a historic milestone, and we're looking forward to delivering this breakthrough therapy for animal health,' she added.
Gallant's first stem cell therapy kit is aimed at tackling a painful mouth condition in cats called Feline Chronic Gingivostomatitis (FCGS). It is on track for FDA approval in early 2026, the company said. If approved, the product could revolutionise how medical conditions in pets are treated.
The primary function of stem cells is self-repair or regeneration. Unlike other cells in our body, stem cells have the unique ability to transform into different types of cells, each serving a specific function.
Stem cells hold great potential for medical research and treatments because they can help repair damaged tissues and organs in the body. Their healing potential is also being explored in regards to humans with thousands of legitimate clinical trials currently underway.
While most stem cell therapy treatments require the cells from a patient or donor with matching tissue to be harvested, Gallant's approach is slightly different and said to be more convenient.
This is because the company uses ready-to-use cells from donor animals, even if they are a different species. Despite some encouraging early results, it is important to remember that stem cell therapy is still an experimental field.
For example, studies have shown that stem cell treatments helped to ease the pain and improved mobility of dogs with arthritis for at least two years. However, similar stem cell treatments targeted at kidney diseases in cats offered mixed results.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
28 minutes ago
- Business Standard
Sunil Mittal, Warburg Pincus eye 49% in Haier India at steep discount
Sunil Mittal's family office and US-based private equity major Warburg Pincus have submitted a bid to acquire a 49 per cent stake in Haier India at a sharply reduced valuation of ₹6,000 crore ($720 million), according to people familiar with the matter. The Chinese parent, Haier Group, had initially sought a valuation of around $2 billion (₹17,100 crore), but offers were significantly lower, said one of the persons, asking not to be named as the discussions are private. Haier is now weighing whether to proceed with the deal or wait for improved market conditions, the person added. As part of the proposed transaction, Haier India employees are expected to acquire a 2 per cent stake, while a public listing is being considered within two years to provide an eventual exit route for the Chinese firm, the people said. 'After the deal, the buyer will have to pay a steep brand usage fees and royalties to the Chinese parent, which has dampened the valuation,' said a person close to the development. Haier, which fully owns the Indian subsidiary, has been exploring a potential exit for several months and even held early-stage discussions with Reliance Industries Ltd, India's largest conglomerate, according to the people. Emails sent to Haier, Mittal's office, and Warburg Pincus on Friday went unanswered until the press time. The proposed deal comes amid a broader trend of Chinese firms paring back their India exposure following geopolitical tensions and growing scrutiny of Chinese investments by India. In March last year, Chinese automaker SAIC Motor agreed to sell a majority stake in its Indian subsidiary MG Motors India to the Sajjan Jindal group. In May, Ant Group exited its investment in Paytm through $246 million worth via block trades. Haier entered India in 2004 and holds a 14 per cent share of the refrigerator market. Its presence in other categories — including washing machines, televisions, and air conditioners — remains in the single digit. India's household appliances market is projected to reach $64.3 billion in 2025, growing at a 7.3 percent CAGR through 2030, according to data from Statista.
Indian Express
an hour ago
- Indian Express
Hamas government office rejects US accusation of involvement in Gaza aid site attack
A Hamas government media office rejected accusations by the US State Department that the group was involved in a Saturday attack that injured two Americans at an aid distribution site in Gaza, it said on Sunday. The US and Israel-backed Gaza Humanitarian Foundation said on Saturday the injured American aid workers were receiving medical treatment after a grenade attack caused non-life-threatening injuries. A representative for UG Solutions, a North Carolina-based company providing security at GHF's aid distribution sites in Gaza, told Reuters on Sunday that the injured Americans were employed as private security contractors. The contractors were former US special forces and did not open fire after they were injured in order to avoid risking harm to nearby civilians, the person said. The Hamas-run media office described the US accusation as misleading, saying it was aimed at justifying 'the continued killing and starvation of Palestinian civilians'. 'We categorically and unequivocally reject the claims issued by the US State Department alleging that the Palestinian resistance threw explosives at American personnel operating at sites run by the so-called 'Gaza Humanitarian Foundation – GHF,' it said in a statement.
Time of India
an hour ago
- Time of India
Costly Drug Now Free For Needy Patients With Rare Skin Disease: Doctors & NGO
Nagpur: Needy patients suffering from a rare and painful skin disorder, Autoimmune Blistering Disease, can now receive the costly drug, Rituximab, free of charge, thanks to the initiative by the Pune-based foundation, AIBDF. The announcement came during a doctors' and public awareness programme organised by the Vidarbha Dermatology Society (VDS) attended by over 200 dermatologists from across Vidarbha. "This disease is rare but deadly, and incredibly painful. Our foundation provides Rituximab injection free of cost to needy patients so they can access the best treatment," said Dr Vikrant Saoji, a senior dermatologist. Suratwala explains that he started AIBDF in memory of his late wife, Jayshree Suratwala, who tragically lost her life to this disease during the pandemic. "I wanted to ensure that no one else suffers the way she did," he said. Senior dermatologist Dr Vinit Dubey from Chandrapur sent the very first patient to AIBDF in 2023. "The patient came from a very poor family," he said, adding, "Thanks to AIBDF, my patient received the expensive medicine for free and is now doing well." Dr Asra Khumushi, president of VDS, says the initiative is a game-changer for many underprivileged patients. "I have several patients with autoimmune blistering diseases, and many come from low-income backgrounds. Steroids are often prescribed but have severe side effects. Rituximab is the most proven and effective drug. Thanks to this NGO, it's possible now for many poor patients to get this treatment," Dr Khumushi explains. Dr Nitin Barde, another dermatologist, highlighted the financial relief for patients. "The entire treatment still adds up to around Rs one lakh. The foreign version costs over Rs three lakh per dose. So, getting this drug free of cost is a huge relief for patients," he says. Jayant Hemade, co-founder of AIBDF, and a family friend of Suratwala, said the NGO has far helped 25 patients. "Until now, the foundation was entirely funded by Suratwala. But we've recently secured CSR certification and will start accepting corporate support," Hemade said. He urged both patients and dermatologists to spread the good word. VDS secretary Dr Priyanka Magia discussed the importance of early diagnosis. "Hundreds of dermatologists across Vidarbha are now aware of this service. I urge anyone experiencing symptoms of this disease to consult a dermatologist as soon as possible, because patients must go through specialists to avail this benefit," Dr Magia advises. According to doctors, AIIMS Nagpur treated 70 patients with autoimmune blistering diseases in the past three years, highlighting the growing need for accessible treatment in the region. Autoimmune Blistering Diseases (AIBDs) * Rare but potentially life-threatening skin disorders * Immune system mistakenly attacks skin and mucous membranes * Causes painful blisters, sores, infections * AIIMS Nagpur treated 70 patients in just 3 years — significant for such a rare illness * Often treated with steroids, but these have serious side effects * Rituximab is the most proven and effective drug * AIBDF now provides Rituximab free of cost to needy patients * 25 patients helped so far by the foundation
